drugset
drugset / Trial / NCT05159895

Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects

NCT05159895 ↗

Phase 1 Completed 8 enrolled Dizal Pharmaceuticals
NaSingle-groupOpen-labelOther

Summary

This is a phase 1, open-label, ADME study with single oral administration of \[14C\]-DZD9008 in healthy subjects.

Timeline

Start
2021-09-24
Primary completion
2022-03-30
Completion
2022-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Sunvozertinib Small molecule 100 mg Oral

Indications

No indication recorded.